Profile
Danute M.
Bankaitis-Davis worked as a Research Scientist at Amgen, Inc. from 1992 to 1998.
She also worked as a Principal at Syntex Corp.
and as an Executive Vice President at Source Precision Medicine, Inc. Dr. Bankaitis-Davis received her undergraduate and graduate degrees from Cleveland State University and her doctorate degree from The University of North Carolina at Charlotte.
Former positions of Danute M. Bankaitis-Davis
| Companies | Position | End |
|---|---|---|
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01/01/1998 |
| Syntex Corp. | Corporate Officer/Principal | - |
Source Precision Medicine, Inc.
 Source Precision Medicine, Inc. Medical SpecialtiesHealth Technology Source Precision Medicine, Inc. develops and commercializes diagnostic biomarker panels. It develops an integrated molecular diagnostic system, which includes quantitative polymerase chain reaction assays, target specific gene expression ranges, and latent class and proprietary enumeration methodologies that measure vital signs of the cell. Its assays and tests measure RNA-transcript-based gene expression in whole blood using quantitative polymerase chain reaction optimized for clinical use in a commercial setting. The company was founded in 1998 and is headquartered in Boulder, CO. | Corporate Officer/Principal | - |
Training of Danute M. Bankaitis-Davis
| The University of North Carolina at Charlotte | Doctorate Degree |
| Cleveland State University | Graduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Private companies | 2 |
|---|---|
Source Precision Medicine, Inc.
Source Precision Medicine, Inc. Medical SpecialtiesHealth Technology Source Precision Medicine, Inc. develops and commercializes diagnostic biomarker panels. It develops an integrated molecular diagnostic system, which includes quantitative polymerase chain reaction assays, target specific gene expression ranges, and latent class and proprietary enumeration methodologies that measure vital signs of the cell. Its assays and tests measure RNA-transcript-based gene expression in whole blood using quantitative polymerase chain reaction optimized for clinical use in a commercial setting. The company was founded in 1998 and is headquartered in Boulder, CO. | Health Technology |
| Syntex Corp. | Health Technology |
- Stock Market
- Insiders
- Danute M. Bankaitis-Davis
